Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-la

Authors : Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Béné MC, Zweegman S, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Stoppa AM, van de Donk NWCJ, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Krevvata M, Zhang K, de Boer C, Vara S, Kampfenkel T, Vanquickelberghe V, Vermeulen J, Avet-Loiseau H, Sonneveld P
Year : 2021
Journal : Lancet Oncol

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.

Authors : Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J
Year : 2020
Journal : Leukemia
Volume : 34
Pages : 224-233

Mesenchymal Stem/Stromal Cells in Immunity and Disease: A Better Understanding for an Improved Use.

Authors : Merimi M, Lagneaux L, Moussa Agha D, Lewalle P, Meuleman N, Burny A, Fahmi H, Najar M
Year : 2020
Journal : J Clin Med
Volume : 9

COVID-19, impact on myeloma patients.

Authors : Dufour I, Raedemaeker J, Andreozzi F, Verstraete G, Bailly S, Delforge M, Storms P, Jacquy C, Van de Velde A, Mineur P, Lejeune M, Bauwens D, Van Obbergh F, Kentos A, Nguyen J, Fostier K, De Weweire A, Meuleman N, Vekemans MC
Year : 2020
Journal : Ann Hematol
Volume : 99
Pages : 1947-1949

The Impact of Cell-Expansion and Inflammation on The Immune-Biology of Human Adipose Tissue-Derived Mesenchymal Stromal Cells.

Authors : Buyl K, Merimi M, Rodrigues RM, Agha DM, Melki R, Vanhaecke T, Bron D, Lewalle P, Meuleman N, Fahmi H, Rogiers V, Lagneaux L, Kock J, Najar M
Year : 2020
Journal : J Clin Med
Volume : 9

Impact of Bone Marrow miR-21 Expression on Acute Myeloid Leukemia T Lymphocyte Fragility and Dysfunction.

Authors : Moussa Agha D, Rouas R, Najar M, Bouhtit F, Fayyad-Kazan H, Lagneaux L, Bron D, Meuleman N, Lewalle P, Merimi M
Year : 2020
Journal : Cells
Volume : 9

Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs.

Authors : Moussa Agha D, Rouas R, Najar M, Bouhtit F, Naamane N, Fayyad-Kazan H, Bron D, Meuleman N, Lewalle P, Merimi M
Year : 2020
Journal : Int J Mol Sci
Volume : 21

Importance of Crosstalk Between Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles.

Authors : Dubois N, Crompot E, Meuleman N, Bron D, Lagneaux L, Stamatopoulos B
Year : 2020
Journal : Front Oncol
Volume : 10
Pages : 1422

Aging of Bone Marrow Mesenchymal Stromal Cells: Hematopoiesis Disturbances and Potential Role in the Development of Hematologic Cancers.

Authors : Massaro F, Corrillon F, Stamatopoulos B, Meuleman N, Lagneaux L, Bron D
Year : 2020
Journal : Cancers (Basel)
Volume : 13

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

Authors : Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S
Year : 2019
Journal : N Engl J Med
Volume : 381
Pages : 727-738

Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres.

Authors : Poirel HA, Vanspauwen M, Macq G, De Geyndt A, Maertens J, Willems E, Selleslag D, Poiré X, Theunissen K, Graux C, Kerre T, Zachée P, Meuleman N, De Becker A, Verlinden A, Van Obbergh F, Schuermans C, de Wilde V, Jaspers A, Pranger D, Deeren D, van Riet I, Vaes E, Beguin Y
Year : 2019
Journal : Bone Marrow Transplant
Volume : 54
Pages : 1434-1442

Reciprocal immuno-biological alterations occur during the co-culture of natural killer cells and adipose tissue-derived mesenchymal stromal cells.

Authors : Najar M, Fayyad-Kazan M, Merimi M, Meuleman N, Bron D, Fayyad-Kazan H, Lagneaux L
Year : 2019
Journal : Cytotechnology
Volume : 71
Pages : 375-388

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Authors : Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, DRozario JM, Dimopoulos MA, Martínez S, Extremera S, Kahatt C, Alfaro V, Carella AM, Meuleman N, Hájek R, Symeonidis A, Min CK, Cannell P, Ludwig H, Sonneveld P, Mateos MV
Year : 2019
Journal : Ann Hematol
Volume : 98
Pages : 2139-2150

Marginal zone lymphomas: second most common lymphomas in older patients.

Authors : Bron D, Meuleman N
Year : 2019
Journal : Curr Opin Oncol
Volume : 31
Pages : 386-393

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Authors : Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P
Year : 2019
Journal : Lancet
Volume : 394
Pages : 29-38

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Authors : Leleu X, Fouquet G, Richez V, Guidez S, Duhamel A, Machuron F, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Roussel M, Jaccard A, Pétillon MO, Belhadj-Merzoug K, Lepeu G, Chrétien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Attal M, Moreau P, Avet-Loiseau H, Hulin C, Facon T
Year : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 4224-4230

Mesenchymal stromal cells and natural killer cells: a complex story of love and hate.

Authors : Najar M, Fayyad-Kazan M, Merimi M, Burny A, Bron D, Fayyad-Kazan H, Meuleman N, Lagneaux L
Year : 2019
Journal : Curr Stem Cell Res Ther
Volume : 14(1)
Pages : 14-21

Adult T-cell leukaemia-lymphoma: Pathogeny and clinical recommendations.

Authors : Vercruyssen M, Van den Broeke A, Salaroli A, Nguyen P, de Wind A, Meuleman N, Bron D
Year : 2019
Journal : Belgian J Hematology
Volume : 10
Pages : 277-284

Immunomodulatory effects of foreskin mesenchymal stromal cells (FSK-MSCs) on natural killer (NK) cells.

Authors : Najar M, Fayyad-Kazan M, Meuleman N, Bron D, Fayyad-Kazan H, Lagneaux L
Year : 2018
Journal : J Cell Physiol
Volume : 233(7)
Pages : 5243-54

The Micronome of Mesenchymal Stromal Cells is partially responsive to Inflammation.

Authors : Fayyad-Kazan H, Fayyad-Kazan M, Merimi M, Meuleman N, Bron D, Lagneaux L, Najar M
Year : 2018
Journal : Cell Biol Int
Volume : 42(2)
Pages : 254-260